VEGF, VEGFR2 and GSTM1 Polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era

This study aimed to investigate the roles of VEGF c.-2595C>A (rs699947), c.-1154G>A (rs1570360), c.-634G>C (rs2010963), c.*237C>T (rs3025039), VEGFR2 c.-906T>C (rs2071559) and c.889G>A (rs2305948) SNPs, and GSTM1 andGSTT1 genes in outcome of MM patients treated with thalidomide-based regimen.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Angelo Brito, Leisa Lopes-Aguiar, Marcia Delamain, Gustavo Lourenco, Ericka Costa, Gislaine Oliveira, Jose Vassallo, Carmino de Souza, Carmen Lima Source Type: research